ThePolitibase
S. 146IntroducedHEALTH

Cap Insulin Prices Act

Digestive and metabolic diseases · Drug therapy · Employee benefits and pensions
Sponsor
Sen. Hawley, Josh [R-MO]
R · MO
Key facts
Introduced: Jan 30, 2023
Chamber: Senate
Cosponsors: 1
Congress: 118th
Latest action · Jun 12, 2024
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-558.

Summary

Cap Insulin Prices Act

This bill reduces cost-sharing for insulin under private health insurance and the Medicare prescription drug benefit.

Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $25 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2024.

The bill caps cost-sharing under the Medicare prescription drug benefit for a month's supply insulin products at $25 beginning in 2024. The current cap on insulin products under Medicare is $35 per month.

Summary by Congressional Research Service.

Timeline

  1. Jun 12, 2024
    Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-558.
  2. Jan 30, 2023
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  3. Jan 30, 2023
    Introduced in Senate

Cosponsors

In the News

View official record on Congress.gov →
Make your voice heard

Contact your representatives about this bill in under 2 minutes.

📬 Contact Your Reps →